Item 1. Legal Proceedings

Abbott is involved in various claims, legal proceedings and investigations as described in our Annual Report on Form 10-K for the year ended December 31, 2020.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

	(c)	Issuer Purchases of Equity Securities


						(d) Maximum
						Number (or
					(c) Total Number	Approximate
					of Shares (or	Dollar Value) of
	(a) Total				Units) Purchased	Shares (or Units)
	Number of		(b) Average		as Part of	that May Yet Be
	Shares (or		Price Paid per		Publicly	Purchased Under
	Units)		Share (or		Announced Plans	the Plans or
Period	Purchased		Unit)		or Programs	Programs
July 1, 2021 – July 31, 2021	450,000	(1)	$	120.849	450,000	$	2,540,924,508	(2)
August 1, 2021 – August 31, 2021	2,175,000	(1)		123.265	2,175,000		2,272,822,841	(2)
September 1, 2021 – September 30, 2021	3,002,035	(1)		120.814	3,000,000		1,910,394,012	(2)
Total	5,627,035	(1)	$	121.764	5,625,000	$	1,910,394,012	(2)

1.	These shares include the shares deemed surrendered to Abbott to pay the exercise price in connection with the exercise of employee stock options – 0 in July, 0 in August, 2,035 in September; and

These shares do not include the shares surrendered to Abbott to satisfy tax withholding obligations in connection with the vesting of restricted stock or restricted stock units.

2.	On October 11, 2019, the board of directors authorized the repurchase of up to $3 billion of Abbott common shares, from time to time.

Previous: Item 4. Controls and Procedures · Next: Item 6. Exhibits